Drugmakers to remove incentives for sales reps marketing antibiotics; Mylan CEO defends EpiPen pricing; fitness trackers don't help people lose weight
Some U.S. hospitals still haven't received Valeant discounts; U.N. General Assembly will discuss antibiotic resistance; AstraZeneca diabetes drugs lowered blood sugar in study
England's NHS delays hep-C coverage due to pricing; Google reports 21% revenue growth; U.S. and U.K. announce partnership for antibiotic development
Hospitals struggle with high drug costs; the FDA approves new weight loss device; the ADA asks docs not to tweet, but they did anyway
The goal is to develop medications that move beyond the high-toxicity and low-efficacy profiles of older drugs.
The Medicines Company's commercial lead for infection disease care talks about its breakthrough antidote for carbapenem-resistant enterobacteriaceae.
- Five things for pharma marketers to know: Wednesday, March 22, 2017
- Drugmakers target severe asthma patients with biologics, but payers raise pricing issue
- Novartis aims to bring first oral asthma drug to market in two decades
- What five different pharma marketing careers look like
- Veeva and QuintilesIMS tussle over customer reference data
- 2017 Healthcare Marketers Trend Report: All the data in one place
- Infographic: What's next for the point of care market
- Drugmakers again boost DTC spending, to $5.6 billion in 2016
- Digital IDs become focus as drugmakers seek to track doctors' behavior online
- Some CME experts remain skeptical when it comes to social media